Ost-müük Rhythm Pharma - RYTM CFD
Lisa lemmikuks- Kokkuvõte
- Ajaloolised andmed
- Sündmused
- Tuluaruanne
- Bilanss
- Rahavood
- Omand
Kauplemistingimused
| Hinnavahe | 0.09 | ||||||||
|
Pika positsiooni ööpäeva tasu
Long position overnight fee
Mine platvormile | -0.025457% | ||||||||
|
Lühikese positsiooni ööpäeva tasu
Short position overnight fee
Mine platvormile | 0.003235% | ||||||||
| Ööpäeva tasu aeg | 21:00 (UTC) | ||||||||
| Min kauplemise kogus | 1 | ||||||||
| Valuuta | USD | ||||||||
| Tagatis | 20% | ||||||||
| Aktsiabörs | United States of America | ||||||||
| Kauplemise vahendustasu | 0% |
*Information provided by Capital.com
Rhythm Pharmaceuticals Inc ESG Risk Ratings
High Medium Low Negligible
‘C’ score indicates satisfactory relative ESG performance and moderate degree of transparency in reporting material ESG data publicly.
Võtmestatistika
| Eelmine sulgemine* | 16.41 |
| Avatud* | 16.08 |
| Aastane muutus* | 399.38% |
| Päeva ulatus* | 15.58 - 16.46 |
| 52 nädala ulatus | 3.06-34.99 |
| Keskmine maht (10 päeva) | 637.13K |
| Keskmine maht (3 kuud) | 15.38M |
| Turukapitalisatsioon | 927.87M |
| P/E suhtarv | -100.00K |
| Ringluses olevad aktsiad | 56.85M |
| Tulu | 33.61M |
| EPS | -3.36 |
| Dividendid (% kasumist) | N/A |
| Beeta | 1.71 |
| Järgmine tuluaruande kuupäev | Jul 31, 2023 |
Kõigi andmete allikas on Refinitiv, välja arvatud tärniga märgitud, kus *-ga andmed on esitanud Capital.com
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Sulgemishind | Change (%) | Avamishind | High | Low |
|---|---|---|---|---|---|---|
| May 26, 2023 | 16.28 | 0.20 | 1.24% | 16.08 | 16.54 | 15.50 |
| May 25, 2023 | 16.41 | 0.16 | 0.98% | 16.25 | 16.53 | 15.92 |
| May 24, 2023 | 16.41 | 0.19 | 1.17% | 16.22 | 16.53 | 16.22 |
| May 23, 2023 | 16.49 | -0.44 | -2.60% | 16.93 | 17.91 | 16.47 |
| May 22, 2023 | 17.01 | 0.24 | 1.43% | 16.77 | 17.43 | 16.77 |
| May 19, 2023 | 16.73 | 0.26 | 1.58% | 16.47 | 16.90 | 16.37 |
| May 18, 2023 | 16.44 | 0.15 | 0.92% | 16.29 | 16.66 | 16.22 |
| May 17, 2023 | 16.41 | 0.09 | 0.55% | 16.32 | 16.61 | 16.22 |
| May 16, 2023 | 16.44 | 0.07 | 0.43% | 16.37 | 16.86 | 16.28 |
| May 15, 2023 | 16.84 | 0.35 | 2.12% | 16.49 | 17.20 | 16.22 |
| May 12, 2023 | 16.45 | -0.19 | -1.14% | 16.64 | 16.75 | 16.33 |
| May 11, 2023 | 16.51 | -0.63 | -3.68% | 17.14 | 17.14 | 16.38 |
| May 10, 2023 | 17.38 | 0.21 | 1.22% | 17.17 | 17.67 | 16.97 |
| May 9, 2023 | 17.05 | 0.75 | 4.60% | 16.30 | 17.36 | 16.29 |
| May 8, 2023 | 16.62 | 0.07 | 0.42% | 16.55 | 17.03 | 16.34 |
| May 5, 2023 | 16.61 | 0.31 | 1.90% | 16.30 | 17.29 | 16.30 |
| May 4, 2023 | 16.40 | -1.83 | -10.04% | 18.23 | 18.23 | 16.33 |
| May 3, 2023 | 18.48 | 0.47 | 2.61% | 18.01 | 19.06 | 18.01 |
| May 2, 2023 | 18.69 | 0.21 | 1.14% | 18.48 | 18.95 | 16.93 |
| May 1, 2023 | 20.16 | 0.24 | 1.20% | 19.92 | 20.47 | 19.73 |
Rhythm Pharma Events
| Kellaaeg (UTC) (UTC) | Riik | Sündmus |
|---|---|---|
| Thursday, June 8, 2023 | ||
| Kellaaeg (UTC) (UTC) 18:00 | Riik US
| Sündmus Rhythm Pharmaceuticals Inc Annual Shareholders Meeting Rhythm Pharmaceuticals Inc Annual Shareholders MeetingForecast -Previous - |
| Wednesday, June 21, 2023 | ||
| Kellaaeg (UTC) (UTC) 18:00 | Riik US
| Sündmus Rhythm Pharmaceuticals Inc Annual Shareholders Meeting Rhythm Pharmaceuticals Inc Annual Shareholders MeetingForecast -Previous - |
| Monday, July 31, 2023 | ||
| Kellaaeg (UTC) (UTC) 12:30 | Riik US
| Sündmus Q2 2023 Rhythm Pharmaceuticals Inc Earnings Release Q2 2023 Rhythm Pharmaceuticals Inc Earnings ReleaseForecast -Previous - |
| Monday, November 6, 2023 | ||
| Kellaaeg (UTC) (UTC) 13:30 | Riik US
| Sündmus Q3 2023 Rhythm Pharmaceuticals Inc Earnings Release Q3 2023 Rhythm Pharmaceuticals Inc Earnings ReleaseForecast -Previous - |
- Aastas
- Kvartalis
| 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|
| Kogutulu | 23.638 | 3.154 | 0 | 0 | 0 |
| Kogu tegevuskulu | 202.795 | 173.213 | 136.575 | 146 | 78.417 |
| Müük/Üldine/admin kulud, kokku | 92.032 | 68.486 | 46.125 | 36.55 | 28.08 |
| Uuringud ja arendus | 108.63 | 104.128 | 90.45 | 109.45 | 50.337 |
| Tulud majandustegevusest | -179.157 | -170.059 | -136.575 | -146 | -78.417 |
| Intressitulud (kulu), muud tulud, neto | -1.172 | 0.447 | 2.579 | 5.271 | 4.353 |
| Muud, neto | -0.79 | 100 | 0 | 0 | |
| Netotulu enne makse | -181.119 | -69.612 | -133.996 | -140.729 | -74.064 |
| Netotulu pärast makse | -181.119 | -69.612 | -133.996 | -140.729 | -74.064 |
| Netotulu enne erikulusid | -181.119 | -69.612 | -133.996 | -140.729 | -74.064 |
| Netotulu | -181.119 | -69.612 | -133.996 | -140.729 | -74.064 |
| Total Adjustments to Net Income | 0 | 0 | |||
| Arvestatav tulu, v a erikulud | -181.119 | -69.612 | -133.996 | -140.729 | -74.064 |
| Arvestatav tulu, koos erikuludega | -181.119 | -69.612 | -133.996 | -140.729 | -74.064 |
| Jaotamisele kuuluv netotulu | -181.119 | -69.612 | -133.996 | -140.729 | -74.064 |
| Keskmine jaotamisele kuuluv aktsia kohta | 52.1207 | 49.6003 | 44.1272 | 36.4225 | 31.004 |
| Jaotatav EPS, v a erakorralised kulud | -3.47499 | -1.40346 | -3.03658 | -3.8638 | -2.38885 |
| Dividends per Share - Common Stock Primary Issue | |||||
| Jaotamisele kuuluv normaal-EPS | -3.47499 | -1.40346 | -3.03658 | -3.8638 | -2.38885 |
| Tulu | 23.638 | 3.154 | |||
| Kulud, Kokku | 2.133 | 0.599 | |||
| Brutokasum | 21.505 | 2.555 |
| Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
|---|---|---|---|---|---|
| Kogutulu | 11.469 | 8.79 | 4.284 | 9.066 | 1.498 |
| Tulu | 11.469 | 8.79 | 4.284 | 9.066 | 1.498 |
| Kulud, Kokku | 1.421 | 1.028 | 0.497 | 0.378 | 0.23 |
| Brutokasum | 10.048 | 7.762 | 3.787 | 8.688 | 1.268 |
| Kogu tegevuskulu | 64 | 50.893 | 43.551 | 54.162 | 54.189 |
| Müük/Üldine/admin kulud, kokku | 24.634 | 26.317 | 21.938 | 22.328 | 21.449 |
| Uuringud ja arendus | 37.945 | 23.548 | 21.116 | 31.456 | 32.51 |
| Tulud majandustegevusest | -52.531 | -42.103 | -39.267 | -45.096 | -52.691 |
| Intressitulud (kulu), muud tulud, neto | 0.379 | 0.03 | -1.224 | 0.095 | -0.073 |
| Muud, neto | -0.027 | -0.42 | -0.37 | 0 | 0 |
| Netotulu enne makse | -52.179 | -42.493 | -40.861 | -45.001 | -52.764 |
| Netotulu pärast makse | -52.179 | -42.493 | -40.861 | -45.001 | -52.764 |
| Netotulu enne erikulusid | -52.179 | -42.493 | -40.861 | -45.001 | -52.764 |
| Netotulu | -52.179 | -42.493 | -40.861 | -45.001 | -52.764 |
| Arvestatav tulu, v a erikulud | -52.179 | -42.493 | -40.861 | -45.001 | -52.764 |
| Arvestatav tulu, koos erikuludega | -52.179 | -42.493 | -40.861 | -45.001 | -52.764 |
| Jaotamisele kuuluv netotulu | -52.179 | -42.493 | -40.861 | -45.001 | -52.764 |
| Keskmine jaotamisele kuuluv aktsia kohta | 56.709 | 56.3455 | 51.4009 | 50.398 | 50.3266 |
| Jaotatav EPS, v a erakorralised kulud | -0.92012 | -0.75415 | -0.79495 | -0.89291 | -1.04843 |
| Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | 0 | |
| Jaotamisele kuuluv normaal-EPS | -0.92012 | -0.75415 | -0.79495 | -0.89291 | -1.04843 |
- Aastas
- Kvartalis
| 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|
| Käibevarad kokku | 354.236 | 308.387 | 181.668 | 302.404 | 258.689 |
| Raha ja lühiajalised investeeringud | 333.288 | 294.855 | 172.792 | 292.459 | 252.061 |
| Raha ja ekvivalendid | 127.677 | 59.248 | 100.854 | 62.294 | 49.542 |
| Lühiajalised investeeringud | 205.611 | 235.607 | 71.938 | 230.165 | 202.519 |
| Prepaid Expenses | 4.392 | 8.404 | 5.828 | 6.438 | 5.288 |
| Other Current Assets, Total | 7.415 | 4.103 | 3.048 | 3.507 | 1.34 |
| Total Assets | 382.481 | 329.523 | 187.073 | 308.523 | 260.21 |
| Property/Plant/Equipment, Total - Net | 3.379 | 4.335 | 5.002 | 5.716 | 1.12 |
| Property/Plant/Equipment, Total - Gross | 6.534 | 6.593 | 6.444 | 6.468 | 1.929 |
| Accumulated Depreciation, Total | -3.155 | -2.258 | -1.442 | -0.752 | -0.809 |
| Note Receivable - Long Term | |||||
| Other Long Term Assets, Total | 16.983 | 12.143 | 0.403 | 0.403 | 0.401 |
| Total Current Liabilities | 39.809 | 43.427 | 17.994 | 24.417 | 13.582 |
| Accounts Payable | 4.797 | 5.737 | 4.9 | 10.415 | 7.64 |
| Accrued Expenses | 33.578 | 30.69 | 13.094 | 14.002 | 5.942 |
| Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities, Total | 1.434 | 7 | 0 | ||
| Total Liabilities | 118.219 | 45.372 | 20.545 | 27.503 | 13.954 |
| Total Long Term Debt | 75.81 | 0 | 0 | 0 | 0.372 |
| Other Liabilities, Total | 2.6 | 1.945 | 2.551 | 3.086 | |
| Total Equity | 264.262 | 284.151 | 166.528 | 281.02 | 246.256 |
| Preferred Stock - Non Redeemable, Net | 0 | 0 | 0 | 0 | |
| Common Stock | 0.056 | 0.05 | 0.044 | 0.044 | 0.034 |
| Additional Paid-In Capital | 974.356 | 813.041 | 625.762 | 606.307 | 430.824 |
| Retained Earnings (Accumulated Deficit) | -710.058 | -528.939 | -459.327 | -325.331 | -184.602 |
| Total Liabilities & Shareholders’ Equity | 382.481 | 329.523 | 187.073 | 308.523 | 260.21 |
| Total Common Shares Outstanding | 56.6124 | 50.2836 | 44.2359 | 43.9967 | 34.4107 |
| Long Term Debt | 75.81 | 0 | 0.372 | ||
| Other Equity, Total | -0.092 | -0.001 | 0.049 | ||
| Laekumata arved, neto | 6.224 | 1.025 | |||
| Accounts Receivable - Trade, Net | 6.224 | 1.025 | |||
| Intangibles, Net | 7.883 | 4.658 | |||
| Total Inventory | 2.917 |
| Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
|---|---|---|---|---|---|
| Käibevarad kokku | 317.838 | 354.236 | 361.874 | 249.332 | 253.449 |
| Raha ja lühiajalised investeeringud | 294.582 | 333.288 | 347.795 | 235.596 | 240.964 |
| Raha ja ekvivalendid | 109.661 | 127.677 | 185.087 | 113.207 | 78.537 |
| Lühiajalised investeeringud | 184.921 | 205.611 | 162.708 | 122.389 | 162.427 |
| Prepaid Expenses | 9.652 | 4.392 | 10.751 | 12.029 | 11.623 |
| Total Assets | 345.678 | 382.481 | 389.614 | 277.675 | 284.824 |
| Property/Plant/Equipment, Total - Net | 3.089 | 3.379 | 3.699 | 3.918 | 4.164 |
| Intangibles, Net | 7.669 | 7.883 | 8.097 | 8.311 | 8.527 |
| Other Long Term Assets, Total | 17.082 | 16.983 | 15.944 | 16.114 | 18.684 |
| Total Current Liabilities | 46.029 | 39.809 | 33.098 | 44.57 | 47.274 |
| Accounts Payable | 13.347 | 4.797 | 4.933 | 6.012 | 12.01 |
| Accrued Expenses | 26.989 | 33.578 | 26.405 | 36.249 | 25.824 |
| Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
| Total Liabilities | 125.915 | 118.219 | 108.419 | 82.047 | 49.055 |
| Total Long Term Debt | 77.52 | 75.81 | 72.961 | 34.273 | 0 |
| Deferred Income Tax | |||||
| Other Liabilities, Total | 2.366 | 2.6 | 2.36 | 3.204 | 1.781 |
| Total Equity | 219.763 | 264.262 | 281.195 | 195.628 | 235.769 |
| Common Stock | 0.056 | 0.056 | 0.056 | 0.05 | 0.05 |
| Additional Paid-In Capital | 981.95 | 974.356 | 949.043 | 823.188 | 818.051 |
| Retained Earnings (Accumulated Deficit) | -762.237 | -710.058 | -667.565 | -626.704 | -581.703 |
| Other Equity, Total | -0.006 | -0.092 | -0.339 | -0.906 | -0.629 |
| Total Liabilities & Shareholders’ Equity | 345.678 | 382.481 | 389.614 | 277.675 | 284.824 |
| Total Common Shares Outstanding | 56.8524 | 56.6124 | 55.7563 | 50.4542 | 50.3937 |
| Preferred Stock - Non Redeemable, Net | 0 | 0 | 0 | 0 | 0 |
| Laekumata arved, neto | 8.117 | 6.224 | 3.328 | 1.707 | 0.862 |
| Accounts Receivable - Trade, Net | 8.117 | 6.224 | 3.328 | 1.707 | 0.862 |
| Other Current Assets, Total | 7.415 | ||||
| Property/Plant/Equipment, Total - Gross | 6.534 | ||||
| Accumulated Depreciation, Total | -3.155 | ||||
| Other Current Liabilities, Total | 5.693 | 1.434 | 1.76 | 2.309 | 9.44 |
| Long Term Debt | 77.52 | 75.81 | 72.961 | 34.273 | |
| Total Inventory | 5.487 | 2.917 |
- Aastas
- Kvartalis
| 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|
| Netotulu/algväärtus | -181.119 | -69.612 | -133.996 | -140.729 | -74.064 |
| Raha majandustegevusest | -173.428 | -146.003 | -121.98 | -122.75 | -62.056 |
| Raha majandustegevusest | 1.672 | 1.158 | 0.69 | 0.834 | 0.442 |
| Mittelikviidsed varad | 25.743 | -79.446 | 17.221 | 12.078 | 10.899 |
| Muutused tööjõus | -19.724 | 1.897 | -5.895 | 5.067 | 0.667 |
| Tulu investeeringutelt | 28.029 | -62.159 | 158.531 | -27.97 | -87.148 |
| Kapitalikulutused | -0.281 | -0.434 | -0.214 | -3.385 | -0.722 |
| Muud rahavood investeeringutelt, kokku | 28.31 | -61.725 | 158.745 | -24.585 | -86.426 |
| Rahavood investeeringutelt | 213.828 | 166.481 | 2.009 | 163.474 | 164.686 |
| Aktsiate emiteerimine (tagasiost), neto | 141.49 | 166.481 | 2.009 | 163.474 | 164.686 |
| Rahaline kogumuutus | 68.429 | -41.681 | 38.56 | 12.754 | 15.482 |
| Laenu väljastamine (kustutamine), neto | 72.338 |
| Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
|---|---|---|---|---|---|
| Net income/Starting Line | -52.179 | -181.119 | -138.626 | -97.765 | -52.764 |
| Cash From Operating Activities | -36.433 | -173.428 | -139.428 | -92.441 | -53.632 |
| Cash From Operating Activities | 0.457 | 1.672 | 1.23 | 0.788 | 0.35 |
| Deferred Taxes | 0 | 0 | 0 | ||
| Non-Cash Items | 14.876 | 25.743 | 17.576 | 9.664 | 4.546 |
| Changes in Working Capital | 0.413 | -19.724 | -19.608 | -5.128 | -5.764 |
| Cash From Investing Activities | 18.464 | 28.029 | 68.804 | 108.501 | 72.522 |
| Capital Expenditures | -0.047 | -0.281 | -0.282 | -0.187 | -0.127 |
| Other Investing Cash Flow Items, Total | 18.511 | 28.31 | 69.086 | 108.688 | 72.649 |
| Cash From Financing Activities | -0.133 | 213.828 | 196.463 | 37.899 | 0.399 |
| Issuance (Retirement) of Stock, Net | 1.218 | 141.49 | 121.463 | 0.399 | 0.399 |
| Net Change in Cash | -18.016 | 68.429 | 125.839 | 53.959 | 19.289 |
| Issuance (Retirement) of Debt, Net | -1.351 | 72.338 | 75 | 37.5 | |
| Foreign Exchange Effects | 0.086 |
| Investori nimi | Investori liik | Ringluse protsent | Hoitud osakud | Muutus osakutes | Hoidmise kuupäev | Hinnang käibele |
|---|---|---|---|---|---|---|
| PRIMECAP Management Company | Investment Advisor | 13.3802 | 7607311 | 696169 | 2023-03-31 | LOW |
| Baker Bros. Advisors LP | Hedge Fund | 11.4296 | 6498267 | 143659 | 2023-03-31 | LOW |
| RA Capital Management, LP | Hedge Fund | 9.702 | 5516067 | 0 | 2023-03-31 | LOW |
| Goldman Sachs & Company, Inc. | Research Firm | 9.3015 | 5288370 | 103935 | 2023-03-31 | MED |
| Federated Hermes Global Investment Management Corp. | Investment Advisor/Hedge Fund | 6.8449 | 3891683 | -2412799 | 2023-03-31 | LOW |
| New Enterprise Associates (NEA) | Venture Capital | 5.1182 | 2909956 | -2000000 | 2023-03-31 | LOW |
| The Vanguard Group, Inc. | Investment Advisor/Hedge Fund | 4.6438 | 2640215 | 51822 | 2023-03-31 | LOW |
| State Street Global Advisors (US) | Investment Advisor/Hedge Fund | 4.5945 | 2612188 | -568510 | 2023-03-31 | LOW |
| Frazier Healthcare Partners | Venture Capital | 3.8075 | 2164739 | 270739 | 2023-03-31 | LOW |
| Polar Capital LLP | Investment Advisor/Hedge Fund | 3.078 | 1750000 | 500000 | 2023-03-31 | LOW |
| Alkeon Capital Management LLC | Investment Advisor/Hedge Fund | 2.9722 | 1689842 | -189214 | 2023-03-31 | LOW |
| Rock Springs Capital Management LP | Hedge Fund | 2.8091 | 1597123 | -163742 | 2023-03-31 | LOW |
| BlackRock Financial Management, Inc. | Investment Advisor/Hedge Fund | 2.7993 | 1591546 | 1124 | 2023-03-31 | LOW |
| BlackRock Institutional Trust Company, N.A. | Investment Advisor | 2.2384 | 1272632 | 29158 | 2023-03-31 | LOW |
| Janus Henderson Investors | Investment Advisor/Hedge Fund | 1.9305 | 1097573 | -142580 | 2023-03-31 | LOW |
| Susquehanna International Group, LLP | Investment Advisor | 1.3799 | 784555 | 90513 | 2023-03-31 | MED |
| BlackRock Investment Management (UK) Ltd. | Investment Advisor/Hedge Fund | 1.2987 | 738401 | -10645 | 2023-03-31 | LOW |
| Opaleye Management Inc. | Hedge Fund | 1.2928 | 735000 | 0 | 2023-03-31 | LOW |
| Fidelity Management & Research Company LLC | Investment Advisor | 1.2291 | 698824 | -74204 | 2023-03-31 | LOW |
| Assenagon Asset Management S.A. | Investment Advisor | 1.1679 | 664026 | 200510 | 2023-03-31 | HIGH |
Miks valida Capital.com? Meie numbrid räägivad iseenda eest.
Capital.com Group530K+
Kauplejad
87K+
Igakuiste aktiivsete klientide arv
$46M+
Igakuine investeerimise maht
$31M+
Igakuiselt välja võetud
Kauplemiskalkulaator
Arvutage oma hüpoteetiline võit/kaotus, kui oleksite avanud CFD-tehingu ühel kindlal kuupäeval (valige kuupäev) ja sulgenud teisel kuupäeval (valige kuupäev).
Kauplemise vahendustasu
0
- 1:1
Finantsvõimendus
1:1
- 20
- 100
- 500
- 1000
- 10000
Investeering
Tehingu suurus (võimendus x investeering):
Avamishind
Close
Lühike Pikk
Rhythm Pharma Company profile
Ettevõttest Rhythm Pharma
Rhythm Pharmaceuticals, Inc. on kommertsjärgus biofarmatseutiline ettevõte. Ettevõte keskendub ravi arendamisele geneetiliste rasvumishaiguste jaoks, mida iseloomustab varakult algav raske rasvumine ja rahuldamatu nälg (hüperfagia). Ettevõtte juhtiv tootekandidaat IMCIVREE (setmelanotiid) on tugevatoimeline melanokortiin-4 retseptor (MC4R). IMCIVREE on välja töötatud harvaesinevate geneetiliste rasvumishaiguste raviks. See keskendub melanokortiin-4 retseptorile (MC4R), mis vastutab kehakaalu ja nälja reguleerimise eest. See on suunatud MC4R-radale, et arendada ravimeid harvaesinevate geneetiliste rasvumishaiguste, sealhulgas proopiomelanokortiini (POMC) puudulikkuse rasvumise, leptiini retseptori (LEPR) puudulikkuse rasvumise ja Bardet-Biedli sündroomi (BBS) raviks, Alstromi sündroom, POMC või LEPR heterosügootne puudulikkuse rasvumine, Smith-Magenise sündroom, steroidretseptori koaktivaatori 1 (SRC1) puudulikkuse rasvumine, MC4R puudulikkuse rasvumine ja SH2B adaptervalgu 1 (SH2B1) puudulikkuse rasvumine.
| Industry: | Bio Therapeutic Drugs |
222 Berkeley Street
12th Floor Boston
BOSTON
MASSACHUSETTS 02116
US
Tuluaruanne
- Annual
- Quarterly
Teised on vaadanud veel
Kas otsite jätkuvalt vahendajat, keda saab usaldada?
Ühinege 530,000+ kauplejaga üle kogu maailma, kes valisid kauplemiseks veebisaidi Capital.com